Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Imagine a nephrologist with no biopsy needle, no imaging techniques, no serum creatinine measurement — a nephrologist whose patients need dialysis when they first present for care. This is the predicament of the diabetologist, whose patients with type 1 diabetes routinely present with end-stage pancreatic beta-cell failure and must be informed that they have an incurable condition requiring lifelong rear-guard action against vascular complications. The future may not be so bleak, however. The natural history of the process leading to type 1 diabetes has been charted by prospective studies; robust predictive strategies are in place; and trials of a variety . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Variation and trends in incidence of childhood diabetes in Europe
(2000) · The Lancet · doi:10.1016/s0140-6736(99)07125-1 · Cited by 755
The NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
The Canadian-European Randomized Control Trial Group (1988) · Diabetes · doi:10.2337/diab.37.11.1574 · Cited by 164
Cited by
Regulatory T cells in transplantation tolerance
Wood, K. J., & Sakaguchi, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri1027 · Cited by 1,317
Gale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Self-citationThe role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure
Roep, B. O. (2003) · Diabetologia · doi:10.1007/s00125-003-1089-5 · Cited by 431
Leete, P., Willcox, A., Krogvold, L., Dahl-Jørgensen, K., Foulis, A. K., Richardson, S. J., & Morgan, N. G. (2016) · Diabetes · doi:10.2337/db15-1615 · Cited by 326
The Stem Cell Niche in Regenerative Medicine
Wagers, A. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.018 · Cited by 269
Metadata
- Authors
- Gale, E. A. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1740-1742
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2004326220
- Cited by
- 43
- References
- 7
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes? https://app.cochat.ai/papers/10.1056/nejm200205303462211
- The paper
- Gale, E. A. M. (2002). Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes? New England Journal of Medicine. https://doi.org/10.1056/nejm200205303462211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.